Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
- Conditions
- Type 1 Papillary Renal Cell CarcinomaType 2 Papillary Renal Cell CarcinomaStage III Renal Cell CancerRecurrent Renal Cell CarcinomaStage IV Renal Cell Cancer
- Interventions
- Registration Number
- NCT01688973
- Lead Sponsor
- National Cancer Institute (NCI)
- Brief Summary
This randomized phase II trial studies how well tivantinib with or without erlotinib hydrochloride works in treating patients with metastatic or locally advanced kidney cancer that cannot be removed by surgery. Tivantinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Detailed Description
PRIMARY OBJECTIVES:
I. To assess the response rate (confirmed complete and partial response) of patients with locally advanced or metastatic papillary renal cell carcinoma treated with either ARQ 197 (tivantinib) or ARQ 197 combined with erlotinib (erlotinib hydrochloride).
SECONDARY OBJECTIVES:
I. To assess the progression free survival (PFS) of patients with locally advanced or metastatic papillary renal cell carcinoma treated with either ARQ 197 or ARQ 197 combined with erlotinib.
II. To assess the safety and tolerability of ARQ 197 therapy and ARQ 197 combined with erlotinib.
III. To descriptively assess the role of prior treatment on outcome.
TERTIARY OBJECTIVES:
I. To bank tissue specimens for future use and once funding is obtained to evaluate the expression of tissue correlative biomarkers such as hepatocyte growth factor receptor (c-MET) and epidermal growth factor receptor (EGFR), and to perform exploratory correlation with clinical outcomes.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive tivantinib orally (PO) twice daily (BID) on days 1-28.
ARM II: Patients receive tivantinib PO BID and erlotinib hydrochloride PO once daily (QD) on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for up to 2 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 55
- Patients must have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic, or locally advanced and unresectable; mixed histologies will be allowed provided that they contain >= 50% of the papillary component
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension; x-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; x-rays, scans or physical examinations for non-measurable disease must have been completed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment form
- Patients with metastatic disease who have a resectable primary tumor and are deemed a surgical candidate may have undergone resection; at least 28 days must have elapsed since surgery and patient must have recovered from any adverse effects of surgery
- Patients with a history of brain metastases who are asymptomatic and have not received steroid therapy in the 14 days prior to registration are eligible; anti-seizure medications are allowed provided they are non-enzyme inducing (e.g. topiramate, levetiracetam, gabapentin)
- Patients may have received up to one prior systemic therapy for advanced or metastatic renal cell carcinoma; patients must not have received a MET inhibitor or erlotinib as prior therapy; at least 21 days must have elapsed since completion of prior systemic therapy, 42 days for nitrosoureas or mitomycin C; patients must have recovered from all associated toxicities at the time of registration
- Patients may have received prior radiation therapy, but must have measurable disease outside the radiation port; at least 21 days must have elapsed since completion of prior radiation therapy; patients must have recovered from all associated toxicities at the time of registration
- Patients must not be receiving or planning to receive any other investigational agents
- Patients must have a complete physical examination and medical history within 28 days prior to registration
- Patients must have a Zubrod performance status of 0-2
- White blood cell (WBC) >= 2,000/mcL
- Absolute neutrophil count (ANC) >= 1,000/mcL
- Platelet count >= 75,000/mcL
- Serum bilirubin =< 1.5 x institutional upper limits of normal (ULN)
- Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamic pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) must be =< 1.5 x the institutional ULN unless the liver is involved with the tumor, in which case serum transaminase (SGOT/SGPT) must be =< 5 x the institutional ULN
- Serum creatinine must be =< 2 x the institutional ULN
- Sodium, potassium and calcium must be obtained within 14 days prior to registration
- Patients with a known history of the following corneal diseases are not eligible: dry eye syndrome, Sjogren's syndrome, keratoconjunctivitis sicca, exposure keratopathy, Fuchs' dystrophy or other active disorders of cornea
- Patients known to be human immunodeficiency virus (HIV)-positive and receiving combination anti-retroviral therapy are not eligible
- Patients must be able to take oral medications; patients must not have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease; patients with intractable nausea or vomiting are not eligible
- Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years
- Patients must be offered the opportunity to participate in specimen banking for future translational medicine studies
- All patients must be informed of the investigational nature of this study and must sign and give written informed consent
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm I (tivantinib) Tivantinib Patients receive tivantinib PO BID on days 1-28. Arm II (tivantinib and erlotinib hydrochloride) Erlotinib Hydrochloride Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28. Arm I (tivantinib) Laboratory Biomarker Analysis Patients receive tivantinib PO BID on days 1-28. Arm II (tivantinib and erlotinib hydrochloride) Laboratory Biomarker Analysis Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28. Arm II (tivantinib and erlotinib hydrochloride) Tivantinib Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28.
- Primary Outcome Measures
Name Time Method Response Rate (Confirmed Complete Response or Partial Response), Determined According to Response Evaluation Criteria in Solid Tumors Up to 3 years Best Response is calculated from the sequence of objective statuses. CR: Two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration.
PR: Two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration, but not qualifying as CR.
Stable/no response: At least one objective status of stable/no response documented at least 6 weeks after registration and before progression or symptomatic deterioration, but not qualifying as anything else above.
Increasing disease: Objective status of progression within 12 weeks of registration, not qualifying as anything else above.
Symptomatic deterioration: Objective status of symptomatic deterioration within 12 weeks of registration, not qualifying as anything else above.
- Secondary Outcome Measures
Name Time Method Progression-free Survival (PFS) 30 months From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of progression are censored at date of last contact.
Frequency and Severity of Toxicities, Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 Up to 3 years This study utilized the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 4.0 for toxicity and Serious Adverse Event reporting. Patients were evaluated every two weeks for the first eight weeks and then once every four weeks. If all protocol treatment is delayed more than three weeks, patients were removed from protocol treatment
Trial Locations
- Locations (214)
Riverside Methodist Hospital
🇺🇸Columbus, Ohio, United States
Columbus NCI Community Oncology Research Program
🇺🇸Columbus, Ohio, United States
The Mark H Zangmeister Center
🇺🇸Columbus, Ohio, United States
Alta Bates Summit Medical Center-Herrick Campus
🇺🇸Berkeley, California, United States
Kaiser Permanente Los Angeles Medical Center
🇺🇸Los Angeles, California, United States
Los Angeles County-USC Medical Center
🇺🇸Los Angeles, California, United States
Cedars Sinai Medical Center
🇺🇸Los Angeles, California, United States
Kaiser Permanente-Riverside
🇺🇸Riverside, California, United States
Smilow Cancer Hospital Care Center at Saint Francis
🇺🇸Hartford, Connecticut, United States
Saint Alphonsus Cancer Care Center-Boise
🇺🇸Boise, Idaho, United States
Loyola University Medical Center
🇺🇸Maywood, Illinois, United States
Hematology Oncology Associates of Illinois - Skokie
🇺🇸Skokie, Illinois, United States
Mercy Medical Center-Sioux City
🇺🇸Sioux City, Iowa, United States
Cancer Center of Kansas-Independence
🇺🇸Independence, Kansas, United States
Saint John Macomb-Oakland Hospital
🇺🇸Warren, Michigan, United States
Park Nicollet Clinic - Saint Louis Park
🇺🇸Saint Louis Park, Minnesota, United States
Regions Hospital
🇺🇸Saint Paul, Minnesota, United States
Heartland Regional Medical Center
🇺🇸Saint Joseph, Missouri, United States
Kettering Medical Center
🇺🇸Kettering, Ohio, United States
Geisinger Medical Center
🇺🇸Danville, Pennsylvania, United States
Geisinger Wyoming Valley/Henry Cancer Center
🇺🇸Wilkes-Barre, Pennsylvania, United States
Wenatchee Valley Hospital and Clinics
🇺🇸Wenatchee, Washington, United States
University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
Hematology and Oncology Associates
🇺🇸Chicago, Illinois, United States
Kaiser Permanente-Bellflower
🇺🇸Bellflower, California, United States
Kaiser Permanente-Irvine
🇺🇸Irvine, California, United States
Kaiser Permanente-Cadillac
🇺🇸Los Angeles, California, United States
City of Hope Comprehensive Cancer Center
🇺🇸Duarte, California, United States
Menorah Medical Center
🇺🇸Overland Park, Kansas, United States
Saint Luke's South Hospital
🇺🇸Overland Park, Kansas, United States
Hematology Oncology Associates of Illinois-Highland Park
🇺🇸Highland Park, Illinois, United States
Kaiser Permanente Hospital
🇺🇸Fontana, California, United States
Hines Veterans Administration Hospital
🇺🇸Hines, Illinois, United States
Saint Francis Hospital and Medical Center - Topeka
🇺🇸Topeka, Kansas, United States
Unity Hospital
🇺🇸Fridley, Minnesota, United States
Saint Luke's East - Lee's Summit
🇺🇸Lee's Summit, Missouri, United States
Genesys Regional Medical Center-West Flint Campus
🇺🇸Flint, Michigan, United States
West Michigan Cancer Center
🇺🇸Kalamazoo, Michigan, United States
Sutter Cancer Research Consortium
🇺🇸Novato, California, United States
Sutter Solano Medical Center/Cancer Center
🇺🇸Vallejo, California, United States
United Hospital
🇺🇸Saint Paul, Minnesota, United States
Kansas City NCI Community Oncology Research Program
🇺🇸Prairie Village, Kansas, United States
Beaumont Hospital-Dearborn
🇺🇸Dearborn, Michigan, United States
Kaiser Permanente
🇺🇸Woodland Hills, California, United States
Cancer Center of Kansas - McPherson
🇺🇸McPherson, Kansas, United States
Lake Huron Medical Center
🇺🇸Port Huron, Michigan, United States
Via Christi Hospital-Pittsburg
🇺🇸Pittsburg, Kansas, United States
Lakeview Hospital
🇺🇸Stillwater, Minnesota, United States
Cancer Center of Kansas - Winfield
🇺🇸Winfield, Kansas, United States
Hurley Medical Center
🇺🇸Flint, Michigan, United States
Cancer Center of Kansas - Newton
🇺🇸Newton, Kansas, United States
Cancer Center of Kansas - Parsons
🇺🇸Parsons, Kansas, United States
Genesys Regional Medical Center
🇺🇸Grand Blanc, Michigan, United States
Evergreen Hematology and Oncology PS
🇺🇸Spokane, Washington, United States
Genesys Hurley Cancer Institute
🇺🇸Flint, Michigan, United States
Allegiance Health
🇺🇸Jackson, Michigan, United States
Saint John's Hospital - Healtheast
🇺🇸Maplewood, Minnesota, United States
Hutchinson Area Health Care
🇺🇸Hutchinson, Minnesota, United States
Cancer Center of Kansas-Wichita Medical Arts Tower
🇺🇸Wichita, Kansas, United States
Borgess Medical Center
🇺🇸Kalamazoo, Michigan, United States
Grandview Hospital
🇺🇸Dayton, Ohio, United States
Ridgeview Medical Center
🇺🇸Waconia, Minnesota, United States
New Ulm Medical Center
🇺🇸New Ulm, Minnesota, United States
Veterans Adminstration New Jersey Health Care System
🇺🇸East Orange, New Jersey, United States
Bronson Methodist Hospital
🇺🇸Kalamazoo, Michigan, United States
Glens Falls Hospital
🇺🇸Glens Falls, New York, United States
Metro Minnesota Community Oncology Research Consortium
🇺🇸Saint Louis Park, Minnesota, United States
North Memorial Medical Health Center
🇺🇸Robbinsdale, Minnesota, United States
Iredell Memorial Hospital
🇺🇸Statesville, North Carolina, United States
Minnesota Oncology Hematology PA-Maplewood
🇺🇸Maplewood, Minnesota, United States
Saint Francis Medical Center
🇺🇸Cape Girardeau, Missouri, United States
Saint Rita's Medical Center
🇺🇸Lima, Ohio, United States
Kadlec Clinic Hematology and Oncology
🇺🇸Kennewick, Washington, United States
Cancer Care Northwest - Spokane South
🇺🇸Spokane, Washington, United States
Cancer Center of Western Wisconsin
🇺🇸New Richmond, Wisconsin, United States
Orange Regional Medical Center
🇺🇸Middletown, New York, United States
Genesis Healthcare System Cancer Care Center
🇺🇸Zanesville, Ohio, United States
Minnesota Oncology Hematology PA-Woodbury
🇺🇸Woodbury, Minnesota, United States
Upper Valley Medical Center
🇺🇸Troy, Ohio, United States
Swedish Medical Center-Edmonds
🇺🇸Edmonds, Washington, United States
Geisinger Medical Center-Cancer Center Hazleton
🇺🇸Hazleton, Pennsylvania, United States
Highline Medical Center-Main Campus
🇺🇸Burien, Washington, United States
Liberty Radiation Oncology Center
🇺🇸Liberty, Missouri, United States
Geisinger Medical Group
🇺🇸State College, Pennsylvania, United States
Mount Carmel Health Center West
🇺🇸Columbus, Ohio, United States
Marietta Memorial Hospital
🇺🇸Marietta, Ohio, United States
Knox Community Hospital
🇺🇸Mount Vernon, Ohio, United States
Harrison HealthPartners Hematology and Oncology-Poulsbo
🇺🇸Poulsbo, Washington, United States
Saint Joseph Oncology Inc
🇺🇸Saint Joseph, Missouri, United States
Saint Ann's Hospital
🇺🇸Westerville, Ohio, United States
Gundersen Lutheran Medical Center
🇺🇸La Crosse, Wisconsin, United States
Grant Medical Center
🇺🇸Columbus, Ohio, United States
Licking Memorial Hospital
🇺🇸Newark, Ohio, United States
Miami Valley Hospital
🇺🇸Dayton, Ohio, United States
Southern Ohio Medical Center
🇺🇸Portsmouth, Ohio, United States
Skagit Valley Hospital
🇺🇸Mount Vernon, Washington, United States
Samaritan North Health Center
🇺🇸Dayton, Ohio, United States
Springfield Regional Medical Center
🇺🇸Springfield, Ohio, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
🇺🇸Baltimore, Maryland, United States
Kaiser Permanente-San Diego Mission
🇺🇸San Diego, California, United States
Kaiser Permanente-San Diego Zion
🇺🇸San Diego, California, United States
Franciscan Health Indianapolis
🇺🇸Indianapolis, Indiana, United States
University Medical Center of Southern Nevada
🇺🇸Las Vegas, Nevada, United States
Nevada Cancer Research Foundation CCOP
🇺🇸Las Vegas, Nevada, United States
Harborview Medical Center
🇺🇸Seattle, Washington, United States
Minor and James Medical PLLC
🇺🇸Seattle, Washington, United States
Group Health Cooperative-Seattle
🇺🇸Seattle, Washington, United States
Swedish Medical Center-First Hill
🇺🇸Seattle, Washington, United States
University of Washington Medical Center
🇺🇸Seattle, Washington, United States
California Pacific Medical Center-Pacific Campus
🇺🇸San Francisco, California, United States
Abbott-Northwestern Hospital
🇺🇸Minneapolis, Minnesota, United States
Hennepin County Medical Center
🇺🇸Minneapolis, Minnesota, United States
Vanderbilt University/Ingram Cancer Center
🇺🇸Nashville, Tennessee, United States
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
🇺🇸San Antonio, Texas, United States
University Hospital
🇺🇸San Antonio, Texas, United States
University of Texas Health Science Center at San Antonio
🇺🇸San Antonio, Texas, United States
Huntsman Cancer Institute/University of Utah
🇺🇸Salt Lake City, Utah, United States
Wayne State University/Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Saint John Hospital and Medical Center
🇺🇸Detroit, Michigan, United States
University of Oklahoma Health Sciences Center
🇺🇸Oklahoma City, Oklahoma, United States
Associates In Womens Health
🇺🇸Wichita, Kansas, United States
Cancer Center of Kansas - Wellington
🇺🇸Wellington, Kansas, United States
Swedish Cancer Institute-Issaquah
🇺🇸Issaquah, Washington, United States
Fred Hutchinson Cancer Research Center
🇺🇸Seattle, Washington, United States
United General Hospital
🇺🇸Sedro-Woolley, Washington, United States
Sparrow Hospital
🇺🇸Lansing, Michigan, United States
Saint Mary Mercy Hospital
🇺🇸Livonia, Michigan, United States
Saint Mary's of Michigan
🇺🇸Saginaw, Michigan, United States
University of Arizona Cancer Center-Orange Grove Campus
🇺🇸Tucson, Arizona, United States
University of Arizona Cancer Center-North Campus
🇺🇸Tucson, Arizona, United States
The University of Arizona Medical Center-University Campus
🇺🇸Tucson, Arizona, United States
Kaiser Permanente-Anaheim
🇺🇸Anaheim, California, United States
Kaiser Permanente-Baldwin Park
🇺🇸Baldwin Park, California, United States
Mills-Peninsula Medical Center
🇺🇸Burlingame, California, United States
Kaiser Permanente - Harbor City
🇺🇸Harbor City, California, United States
USC / Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Fremont - Rideout Cancer Center
🇺🇸Marysville, California, United States
Kaiser Permanente - Panorama City
🇺🇸Panorama City, California, United States
Stanford Cancer Institute
🇺🇸Palo Alto, California, United States
Kaiser Permanente-San Marcos
🇺🇸San Marcos, California, United States
Sutter Pacific Medical Foundation
🇺🇸Santa Rosa, California, United States
Gene Upshaw Memorial Tahoe Forest Cancer Center
🇺🇸Truckee, California, United States
MedStar Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
Sibley Memorial Hospital
🇺🇸Washington, District of Columbia, United States
Idaho Urologic Institute-Meridian
🇺🇸Meridian, Idaho, United States
George Washington University Medical Center
🇺🇸Washington, District of Columbia, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
NorthShore Hematology Oncology-Libertyville
🇺🇸Libertyville, Illinois, United States
Presence Saint Mary's Hospital
🇺🇸Kankakee, Illinois, United States
Illinois Cancer Specialists-Niles
🇺🇸Niles, Illinois, United States
Siouxland Regional Cancer Center
🇺🇸Sioux City, Iowa, United States
Reid Health
🇺🇸Richmond, Indiana, United States
University of Iowa/Holden Comprehensive Cancer Center
🇺🇸Iowa City, Iowa, United States
Franciscan Saint Francis Health-Beech Grove
🇺🇸Beech Grove, Indiana, United States
Saint Luke's Regional Medical Center
🇺🇸Sioux City, Iowa, United States
Cancer Center of Kansas - Chanute
🇺🇸Chanute, Kansas, United States
Cancer Center of Kansas - Dodge City
🇺🇸Dodge City, Kansas, United States
Cancer Center of Kansas - El Dorado
🇺🇸El Dorado, Kansas, United States
Saint Rose Ambulatory and Surgery Center
🇺🇸Great Bend, Kansas, United States
Hutchinson Regional Medical Center
🇺🇸Hutchinson, Kansas, United States
Cancer Center of Kansas - Fort Scott
🇺🇸Fort Scott, Kansas, United States
Hays Medical Center
🇺🇸Hays, Kansas, United States
Providence Medical Center
🇺🇸Kansas City, Kansas, United States
University of Kansas Cancer Center
🇺🇸Kansas City, Kansas, United States
Lawrence Memorial Hospital
🇺🇸Lawrence, Kansas, United States
Cancer Center of Kansas-Kingman
🇺🇸Kingman, Kansas, United States
Cancer Center of Kansas-Liberal
🇺🇸Liberal, Kansas, United States
Cancer Center of Kansas - Pratt
🇺🇸Pratt, Kansas, United States
Cancer Center of Kansas - Salina
🇺🇸Salina, Kansas, United States
Salina Regional Health Center
🇺🇸Salina, Kansas, United States
Via Christi Regional Medical Center
🇺🇸Wichita, Kansas, United States
Cancer Center of Kansas - Wichita
🇺🇸Wichita, Kansas, United States
Wichita NCI Community Oncology Research Program
🇺🇸Wichita, Kansas, United States
Saint Joseph Mercy Oakland
🇺🇸Pontiac, Michigan, United States
Fairview-Southdale Hospital
🇺🇸Edina, Minnesota, United States
Mercy Hospital
🇺🇸Coon Rapids, Minnesota, United States
Fairview Ridges Hospital
🇺🇸Burnsville, Minnesota, United States
Saint Francis Regional Medical Center
🇺🇸Shakopee, Minnesota, United States
Saint Louis Cancer and Breast Institute-South City
🇺🇸Saint Louis, Missouri, United States
Saint Louis-Cape Girardeau CCOP
🇺🇸Saint Louis, Missouri, United States
Mercy Hospital Saint Louis
🇺🇸Saint Louis, Missouri, United States
University of Rochester
🇺🇸Rochester, New York, United States
Columbia University/Herbert Irving Cancer Center
🇺🇸New York, New York, United States
Kinston Medical Specialists PA
🇺🇸Kinston, North Carolina, United States
Adena Regional Medical Center
🇺🇸Chillicothe, Ohio, United States
Doctors Hospital
🇺🇸Columbus, Ohio, United States
Wayne Hospital
🇺🇸Greenville, Ohio, United States
Good Samaritan Hospital - Dayton
🇺🇸Dayton, Ohio, United States
Atrium Medical Center-Middletown Regional Hospital
🇺🇸Franklin, Ohio, United States
Dayton NCI Community Oncology Research Program
🇺🇸Dayton, Ohio, United States
Grady Memorial Hospital
🇺🇸Delaware, Ohio, United States
Blanchard Valley Hospital
🇺🇸Findlay, Ohio, United States
Fairfield Medical Center
🇺🇸Lancaster, Ohio, United States
Greene Memorial Hospital
🇺🇸Xenia, Ohio, United States
University of Pennsylvania/Abramson Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Rapid City Regional Hospital
🇺🇸Rapid City, South Dakota, United States
Baylor University Medical Center
🇺🇸Dallas, Texas, United States
Cancer Care Center at Island Hospital
🇺🇸Anacortes, Washington, United States
Audie L Murphy Veterans Affairs Hospital
🇺🇸San Antonio, Texas, United States
Harrison HealthPartners Hematology and Oncology-Bremerton
🇺🇸Bremerton, Washington, United States
PeaceHealth Saint Joseph Medical Center
🇺🇸Bellingham, Washington, United States
University of California Davis Comprehensive Cancer Center
🇺🇸Sacramento, California, United States
University of Colorado Cancer Center - Anschutz Cancer Pavilion
🇺🇸Aurora, Colorado, United States
Saint Joseph Mercy Hospital
🇺🇸Ann Arbor, Michigan, United States
Michigan Cancer Research Consortium NCORP
🇺🇸Ann Arbor, Michigan, United States
University of Michigan Comprehensive Cancer Center
🇺🇸Ann Arbor, Michigan, United States
Nebraska Methodist Hospital
🇺🇸Omaha, Nebraska, United States
North Kansas City Hospital
🇺🇸Kansas City, Missouri, United States
Research Medical Center
🇺🇸Kansas City, Missouri, United States
Heartland Hematology and Oncology Associates Incorporated
🇺🇸Kansas City, Missouri, United States
Truman Medical Center
🇺🇸Kansas City, Missouri, United States
Saint Luke's Hospital of Kansas City
🇺🇸Kansas City, Missouri, United States
Rice Memorial Hospital
🇺🇸Willmar, Minnesota, United States